Compare BioNTech SE - ADR (BNTX) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Kinross Gold Corporation — how do they compare? BioNTech SE - ADR trades at $90.31 (market cap $22.86B), while Kinross Gold Corporation trades at $23.76 (market cap $28.24B). The key difference: Kinross Gold Corporation is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.61% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | KGC | |
|---|---|---|
Market Cap | $22.86B | $28.24B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $38.06 |
52-Week Low | $83.89 | $15.33 |
Enterprise Value | $6.53B | $26.80B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
KGC trades at $23.48, down 2.73% on the day, amid a bearish technical signal. Fundamentally, the company shows robust health with revenue growth from $3.5B in 2022 to $7.05B in 2025 and a net income margin of 35.99%. Recent quarters have consistently beaten EPS estimates. Analyst consensus is bullish with a $37.20 price target, though technical indicators suggest near-term pressure.
The outlook for KGC is positive based on strong fundamentals and growth trajectory, but investors face near-term technical headwinds and sensitivity to gold prices. The stock presents a value opportunity with a low P/E of 9.99, though execution on production guidance and cost management remain key to realizing upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
